BSX logo

Boston Scientific Stock Price

Symbol: NYSE:BSXMarket Cap: US$155.3bCategory: Healthcare

BSX Share Price Performance

US$102.95
29.17 (39.54%)
17.1% undervalued intrinsic discount
US$124.14
Fair Value
US$102.95
29.17 (39.54%)
17.1% undervalued intrinsic discount
US$124.14
Fair Value
Price US$102.95
AnalystConsensusTarget US$124.14

BSX Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value US$124.14 17.1% undervalued intrinsic discount

Advanced Therapies And Asia Pacific Markets Will Expand Global Scope

1users have liked this narrative
0users have commented on this narrative
36users have followed this narrative

Recent BSX News & Updates

No updates

Boston Scientific Corporation Key Details

US$18.5b

Revenue

US$5.9b

Cost of Revenue

US$12.6b

Gross Profit

US$10.1b

Other Expenses

US$2.5b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
1.69
Gross Margin
68.04%
Net Profit Margin
13.54%
Debt/Equity Ratio
50.6%

Boston Scientific Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About BSX

Founded
1979
Employees
53000
CEO
Michael Mahoney
WebsiteView website
www.bostonscientific.com

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

U.S. Market Performance

  • 7 Days: -0.2%
  • 3 Months: 12.2%
  • 1 Year: 22.4%
  • Year to Date: 7.7%
The Communication Services sector gained 3.4% while the market remained flat over the last week. Meanwhile, the market is actually up 22% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading